SCHEMBL3555283

SCHEMBL3555283

C[C@H](Nc1nccc(-c2cnc3c(C(F)(F)F)cccn23)n1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 6/20 0.47
MAPK13 O15264 11/20 0.45
MAPK9 P45984 5/20 0.45
PRKD3 O94806 1/20 0.45
MAP4K4 O95819 1/20 0.45
LCK P06239 1/20 0.45
LYN P07948 1/20 0.45
MAPK1 P28482 1/20 0.45
AKT2 P31751 1/20 0.45
FLT4 P35916 1/20 0.45
FRK P42685 1/20 0.45
MAPK8 P45983 1/20 0.45
CSNK1A1 P48729 1/20 0.45
CSNK1D P48730 1/20 0.45
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45
CSNK1G2 P78368 1/20 0.45
MAP4K2 Q12851 1/20 0.45
DYRK1A Q13627 1/20 0.45
ERBB4 Q15303 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3548953 0.85 FLT3 (0.49) FLT3MAPK13MAPK9PRKD3MAP4K4
SCHEMBL3552664 0.82 HDAC6 (0.42) MAPK13MAPK14MAPK12MAPK11
SCHEMBL3555802 0.81 FLT3 (0.54) FLT3MAPK13MAPK9PRKD3MAP4K4
SCHEMBL3558657 0.80 AR (0.51)
SCHEMBL3556311 0.80 DYRK1A (0.56) FLT3MAPK13MAPK9PRKD3MAP4K4
SCHEMBL3557012 0.80 CAMK2D (0.47) FLT3MAPK13MAPK9PRKD3MAP4K4
SCHEMBL3551857 0.77 MAPK13 (0.49) FLT3MAPK13MAPK9PRKD3MAP4K4
SCHEMBL3554519 0.76 HDAC4 (0.41) MAPK13MAPK14MAPK12MAPK11
SCHEMBL3554558 0.74 MAPK14 (0.49) FLT3MAPK13MAPK9PRKD3MAP4K4
SCHEMBL3555046 0.72 IDH1 (0.40) FLT3MAPK13LCKMAPK14MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718801-B2 Substituted imidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-05-18 US claimed
US-20080070894-A1 Novel Substituted Imidazole Derivative MSD K.K. (JP) 2008-03-20 US claimed
EP-1790650-A1 NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP claimed
US-7718801-B2 Substituted imidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-05-18 US disclosed
US-20080070894-A1 Novel Substituted Imidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
EP-1790650-A1 NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070894-A1 Novel Substituted Imidazole Derivative PLK1, CDK1, CDK11A FLT3 23/4885MAPK13 678/4885MAPK9 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.